SeraCare Life Sciences
Symbol:
SRLS
Class Period:
Status:
Investigating
Documents:
Pomerantz is investigating claims on behalf of investors of SeraCare Life Sciences (“SeraCare” or the “Company”) (NASDAQ: SRLS) (ISIN: US81747T1043) concerning the proposed acquisition of SeraCare by Linden Capital Partners (“Linden”) in a cash transaction valued at approximately $82 million.
The investigation concerns whether the SeraCare directors are breaching their fiduciary duties by failing to adequately shop the Company and maximize shareholder value. Under the terms of the agreement, SeraCare shareholders would receive $4.00 in cash per share of SeraCare common stock. However, SeraCare has traded above $4.00 per share and at least one analyst has set a target price of $5.00 per share.
SeraCare shareholders seeking more information about this acquisition are advised to contact Gustavo Bruckner, Esq. at gfbruckner [at] pomlaw [dot] com or 212-661-1100 or toll free at 888-476-6529, ext. 302. Shareholders may also contact Rebecca Jarmon at rjarmon [at] pomlaw [dot] com or 212-661-1100 or 888-476-6529, ext. 314.
